Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Beam Therapeutics ( (BEAM) ) has provided an update.
On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company, agreeing to issue 403,128 shares of its common stock as an upfront payment and up to $89 million in additional milestone payments. This strategic acquisition is expected to enhance Beam’s capabilities and market position, potentially impacting its operations and stakeholders positively.
The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
Beam Therapeutics’ overall stock score is constrained by its financial challenges and unattractive valuation, typical of early-stage biotech companies. While technical indicators show short-term momentum, the lack of profitability and high operational costs are significant concerns.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
Beam Therapeutics Inc. operates in the life sciences industry, focusing on developing innovative therapies through advanced genetic engineering technologies.
Average Trading Volume: 2,173,185
Technical Sentiment Signal: Sell
Current Market Cap: $1.76B
Find detailed analytics on BEAM stock on TipRanks’ Stock Analysis page.